Akira Nishiyama Selected Research

Glucose (Dextrose)

4/2024	Exogenous Thyroxine Increases Cardiac GLUT4 Translocation in Insulin Resistant OLETF Rats.
1/2022	Chronic angiotensin receptor activation promotes hepatic triacylglycerol accumulation during an acute glucose challenge in obese-insulin-resistant OLETF rats.
1/2022	Improved lipogenesis gene expression in liver is associated with elevated plasma angiotensin 1-7 after AT1 receptor blockade in insulin-resistant OLETF rats.
11/2021	Kidney Outcomes Associated With SGLT2 Inhibitors Versus Other Glucose-Lowering Drugs in Real-world Clinical Practice: The Japan Chronic Kidney Disease Database.
11/2021	Chronic AT1 blockade improves hyperglycemia by decreasing adipocyte inflammation and decreasing hepatic PCK1 and G6PC1 expression in obese rats.
11/2021	Sodium/glucose cotransporter 2 and renoprotection: From the perspective of energy regulation and water conservation.
11/2021	Relation of the Metabolic Syndrome to Incident Colorectal Cancer in Young Adults Aged 20 to 49 Years.
10/2021	Fasting Plasma Glucose and Incident Colorectal Cancer: Analysis of a Nationwide Epidemiological Database.
7/2020	Failure to confirm a sodium-glucose cotransporter 2 inhibitor-induced hematopoietic effect in non-diabetic rats with renal anemia.
1/2020	Effects of an SGLT2 inhibitor on the salt sensitivity of blood pressure and sympathetic nerve activity in a nondiabetic rat model of chronic kidney disease.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Akira Nishiyama Research Topics

Disease

93	Hypertension (High Blood Pressure) 04/2024 - 01/2001
30	Fibrosis (Cirrhosis) 01/2023 - 10/2005
25	Proteinuria 02/2022 - 01/2004
23	Neoplasms (Cancer) 04/2024 - 09/2014
23	Albuminuria 01/2023 - 09/2008
21	Insulin Resistance 04/2024 - 10/2007
20	Type 2 Diabetes Mellitus (MODY) 01/2023 - 09/2008
19	Chronic Renal Insufficiency 12/2023 - 01/2009
18	Diabetic Nephropathies (Diabetic Nephropathy) 01/2019 - 10/2004
16	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2022 - 05/2010
15	Inflammation (Inflammations) 02/2024 - 01/2008
13	Ischemia 01/2023 - 11/2003
12	Wounds and Injuries (Trauma) 01/2022 - 04/2005
12	Obesity 11/2021 - 02/2012
10	Cardiovascular Diseases (Cardiovascular Disease) 12/2023 - 10/2005
9	Glucose Intolerance 04/2024 - 10/2007
9	Body Weight (Weight, Body) 01/2022 - 01/2002
8	Stroke (Strokes) 04/2024 - 05/2006
8	Hyperglycemia 11/2022 - 10/2004
8	Hypoxia (Hypoxemia) 06/2021 - 09/2009
8	Reperfusion Injury 01/2021 - 05/2005
8	Hypertrophy 01/2019 - 07/2007
7	Kidney Diseases (Kidney Disease) 01/2023 - 05/2006
7	IGA Glomerulonephritis (IGA Nephropathy) 01/2022 - 05/2006
7	Anemia 06/2021 - 09/2017
6	Heart Failure 04/2024 - 04/2007
6	Colorectal Neoplasms (Colorectal Cancer) 01/2023 - 01/2019
5	Hemorrhage 03/2023 - 01/2018
5	Acute Kidney Injury (Acute Renal Failure) 01/2020 - 11/2003
4	Hepatocellular Carcinoma (Hepatoma) 11/2023 - 01/2020
4	Adenocarcinoma 01/2023 - 03/2015
4	Pain (Aches) 12/2022 - 08/2014
4	Dyslipidemias (Dyslipidemia) 01/2022 - 12/2012
4	Glycosuria 07/2020 - 12/2015
4	Necrosis 01/2019 - 11/2003
4	Sclerosis 03/2010 - 07/2005
3	Myocardial Infarction 04/2024 - 10/2015

Drug/Important Bio-Agent (IBA)

51	Angiotensin IIIBA 01/2023 - 02/2002
46	SaltsIBA 02/2024 - 01/2003
33	Proteins (Proteins, Gene)FDA Link 01/2023 - 02/2004
31	AldosteroneIBA 01/2022 - 01/2004
29	Glucose (Dextrose)FDA LinkGeneric 04/2024 - 03/2005
23	AngiotensinogenIBA 01/2021 - 01/2003
21	ReninIBA 01/2020 - 02/2002
20	Prorenin ReceptorIBA 12/2023 - 05/2006
17	Antihypertensive Agents (Antihypertensives)IBA 04/2024 - 09/2007
16	SodiumIBA 01/2023 - 03/2003
16	olmesartanIBA 01/2023 - 07/2004
15	Sodium-Glucose Transporter 2 InhibitorsIBA 04/2024 - 05/2016
15	Messenger RNA (mRNA)IBA 11/2021 - 05/2006
14	Reactive Oxygen Species (Oxygen Radicals)IBA 04/2024 - 01/2001
14	Angiotensin Receptor AntagonistsIBA 01/2023 - 08/2008
13	Eplerenone (Inspra)FDA LinkGeneric 01/2021 - 04/2004
12	Angiotensin Receptors (Angiotensin II Receptor)IBA 09/2022 - 04/2012
10	CreatinineIBA 01/2023 - 08/2011
10	AngiotensinsIBA 01/2022 - 01/2003
10	Insulin (Novolin)FDA Link 01/2022 - 10/2007
10	Mineralocorticoid Receptors (Mineralocorticoid Receptor)IBA 01/2021 - 04/2005
10	NADPH Oxidases (NAD(P)H oxidase)IBA 01/2014 - 05/2005
9	CateninsIBA 12/2023 - 03/2015
8	Peptides (Polypeptides)IBA 01/2020 - 10/2004
7	Sodium-Glucose Transport ProteinsIBA 04/2024 - 12/2015
7	CollagenIBA 01/2023 - 01/2005
7	Erythropoietin FDA Link 01/2021 - 02/2016
7	Hydralazine (Apresoline)FDA LinkGeneric 03/2020 - 03/2004
6	AntioxidantsIBA 09/2022 - 03/2006
6	AlbuminsIBA 01/2021 - 09/2008
6	Chymases (Chymase)IBA 11/2018 - 08/2008
6	candesartanIBA 01/2018 - 10/2003
6	Superoxides (Superoxide)IBA 01/2014 - 02/2003
6	tempolIBA 01/2012 - 03/2004
5	Blood Glucose (Blood Sugar)IBA 01/2023 - 09/2008
5	Retinaldehyde (Retinal)IBA 10/2022 - 03/2012
5	esaxerenoneIBA 08/2022 - 01/2019
5	Transcription Factors (Transcription Factor)IBA 06/2022 - 11/2013
5	Spironolactone (Aldactone)FDA LinkGeneric 01/2022 - 11/2013
5	Drinking WaterIBA 01/2022 - 07/2004
5	Immunoglobulin A (IgA)IBA 01/2022 - 05/2006
5	Biomarkers (Surrogate Marker)IBA 01/2021 - 12/2014
5	aliskiren FDA Link 10/2018 - 05/2010
4	Mineralocorticoid Receptor AntagonistsIBA 01/2023 - 03/2010
4	Transforming Growth Factors (Transforming Growth Factor)IBA 01/2023 - 09/2009
4	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2023 - 09/2009
4	Triglycerides (Triacylglycerol)IBA 01/2022 - 01/2018
4	Prolyl Hydroxylases (Prolyl Hydroxylase)IBA 06/2021 - 02/2016
4	Adenine FDA LinkGeneric 12/2020 - 09/2017
4	Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)IBA 10/2020 - 06/2009
4	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 10/2020 - 06/2007
4	Valsartan (Vals)FDA Link 03/2020 - 08/2008
4	Glucagon-Like Peptide 1 (GLP 1)IBA 10/2018 - 09/2011
4	Renin InhibitorsIBA 10/2018 - 05/2010
4	Type 1 Angiotensin ReceptorIBA 01/2017 - 10/2003
4	Epoxide HydrolasesIBA 07/2015 - 02/2013
4	FructoseIBA 11/2013 - 09/2009
4	Angiotensin II Type 1 Receptor BlockersIBA 01/2013 - 09/2008

Therapy/Procedure

24	Therapeutics 02/2024 - 07/2005
6	Denervation 02/2024 - 11/2003
5	Surgical Instruments (Clip) 04/2022 - 03/2011
5	Nephrectomy 06/2021 - 11/2003
4	Oral Administration 06/2018 - 12/2010